Merck KGaA (OTCMKTS:MKGAF) Sees Strong Trading Volume – What’s Next?

Shares of Merck KGaA (OTCMKTS:MKGAF) saw unusually-high trading volume on Monday. Approximately 4,500 shares traded hands during trading, an increase of 623% from the previous session’s volume of 622 shares. The stock last traded at $157.00 and had previously closed at $159.4510.

Merck KGaA Stock Performance

The company’s 50-day simple moving average is $160.88 and its 200-day simple moving average is $150.29. The stock has a market cap of $19.69 billion, a price-to-earnings ratio of 23.26 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MKGAF. MASTERINVEST Kapitalanlage GmbH bought a new stake in Merck KGaA during the 2nd quarter worth about $4,896,000. Puzo Michael J bought a new position in shares of Merck KGaA in the second quarter valued at $2,230,000. Somerville Kurt F acquired a new position in shares of Merck KGaA in the second quarter valued at $1,997,000. Pinnacle Holdings LLC acquired a new position in shares of Merck KGaA in the second quarter valued at about $1,487,000. Finally, North Star Asset Management Inc. acquired a new stake in Merck KGaA during the second quarter worth about $1,411,000. Institutional investors own 0.10% of the company’s stock.

Merck KGaA Company Profile

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest operating pharmaceutical and chemical companies. The business serves customers in more than 60 countries through three operating sectors: Healthcare, Life Science and Electronics.

The Healthcare sector develops and markets prescription medicines and specialty therapies, with activities focused on areas including oncology, neurology and immunology, fertility, and endocrinology.